We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Level up your trading with our powerful tools and real-time insights all in one place.
The current AUPH market cap is 1.16B. The company's latest EPS is USD 0.0402 and P/E is 201.00.
| Quarter End | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 44.83M | 54.52M | 45.1M | 54.43M | 57.48M |
| Operating Income | -16.46M | -13.62M | -28.98M | -13.25M | -1.51M |
| Net Income | -11.49M | -13.45M | -26.88M | -10.75M | 722k |
| Year End 31 December 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 50.12M | 45.61M | 135.55M | 175.51M | 239.48M |
| Operating Income | -104.29M | -180.74M | -111.47M | -91.69M | -4.69M |
| Net Income | -102.68M | -180.97M | -108.18M | -78.02M | 5.75M |
| Quarter End | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 548.9M | 555.01M | 548.06M | 516.63M | 523.53M |
| Total Liabilities | 156.61M | 163.14M | 170.11M | 157.16M | 158.91M |
| Total Equity | 392.29M | 391.88M | 377.95M | 359.48M | 364.62M |
| Year End 31 December 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 463.66M | 543.37M | 470.86M | 548.06M | 550.65M |
| Total Liabilities | 55.91M | 64.28M | 65.43M | 170.11M | 173.17M |
| Total Equity | 407.75M | 479.09M | 405.44M | 377.95M | 377.48M |
| Quarter End | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -34.5M | -47.77M | -33.46M | -18.6M | -2.76M |
| Investing | 19.25M | -449k | -6.71M | 49.23M | 10.61M |
| Financing | 2.78M | 447k | -5.13M | -15.05M | -23.32M |
| Year End 31 December 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -69.86M | -157.69M | -79.53M | -33.46M | 44.39M |
| Investing | -158.19M | -103.87M | -60.63M | -6.71M | 39.26M |
| Financing | 194.38M | 221.11M | 2.43M | -5.13M | -49.09M |
| Market Cap | 1.16B |
| Price to Earnings Ratio | 201.00 |
| Price to Sales Ratio | 4.82 |
| Price to Cash Ratio | 13.85 |
| Price to Book Ratio | 3.06 |
| Dividend Yield | - |
| Shares Outstanding | 142.99M |
| Average Volume (1 week) | 2.15M |
| Average Volume (1 Month) | 1.71M |
| 52 Week Change | 50.19% |
| 52 Week High | 10.67 |
| 52 Week Low | 4.71 |
| Spread (Intraday) | 0.01 (0.12%) |
| Company Name | Aurinia Pharmaceuticals Inc |
| Address |
1203-4464 markham street victoria, british columbia V8Z 7X8 |
| Website | https://www.auriniapharma.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
